Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SangStat Med. (SANG) - 10 of 10 analysts say Strong Buy -- Ignore unavailable to you. Want to Upgrade?

To: Darth Vader who wrote (78)	2/12/1998 11:08:00 PM
From: pwrmstr	Read Replies (2) \| Respond to of 184

I don't have time to provide a detailed response at this time, but here is the essence of what I learned in my research. Zenapax has been tested for use during induction therapy during the first 10-12 days after transplantation. If this therapy works some doctors believe that this will eliminate the need for further drug therapy. Here is the bottom line. Induction therapy is highly experimental and unproven. The existing users of Cyclosporin are not eligible for induction therapy or any other type of drug therapy even if they did work because of the high risks associated with switching drugs. Bottom line - Cyclosporin is here to stay and Sangstat is going to do great. Hang in there if you own the stock IMO.